This poster is a study on Live Cell Painting, showcasing drug responses in human primary patient cells with our new non-toxic dye. It presents a novel mix-and-read and non-toxic dye (ChromaLIVE), enabling the first live-cell imaging compound screening.

Our non-toxic dye provides unique phenotypic fingerprints, avoiding sample alterations and loss of crucial kinetic information. The methodology included a high-content screening study on 1,508 FDA-approved compounds from patient biopsy samples, including a unique 3D cell imaging study.

The research successfully identified an optimal treatment regime for a late-stage prostate cancer patient, highlighting the value of our methodology for personalized medicine and the relevance of ChromaLIVE for phenotypic profiling in live cells. By leveraging ChromaLIVE and automated AI image analysis tools like ViQi AutoHCS™, the study predicted drug mechanisms of action (MoA).

This Live Cell Painting approach represents a significant advancement in high-content screening, enabling the detection of dynamic phenotypic changes and contributing to MoA prediction and disease-relevant phenotype quantification.